Company Filing History:
3 out of 247 
1 out of 460 
1 out of 1 Years Active: 1995-2001
Title: The Innovative Contributions of Guillaume Conrath
Introduction
Guillaume Conrath is a notable inventor based in Chatenay-Malabry, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release formulations. With a total of 5 patents to his name, Conrath's work has had a meaningful impact on drug delivery systems.
Latest Patents
One of his latest patents focuses on pharmaceutical compositions in the form of sustained-release tablets based on high molecular weight polysaccharide granules. This invention relates to a delayed-release pharmaceutical composition that consists of at least one active principle and a matrix that provides the delayed-release effect. The matrix is characterized by its composition, which includes pregranulated polysaccharides of high molecular weight, derived from either synthetic or natural sources.
Another significant patent involves pharmaceutical compositions based on dalfopristine and quinupristine, along with their preparation methods. This invention pertains to injectable compositions that contain a combination of dalfopristine and quinupristine, formulated as an aqueous solution. An additive is included to mitigate or reduce the intolerance effects at the injection site.
Career Highlights
Throughout his career, Guillaume Conrath has worked with prominent companies in the pharmaceutical industry, including Rhône-Poulenc Rorer S.A. and Rhodia Chimie. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Conrath has collaborated with notable colleagues such as Gabriel Gousset and Jean-Pierre Collaueri. These partnerships have likely enriched his research and development efforts in the pharmaceutical sector.
Conclusion
Guillaume Conrath's innovative work in pharmaceutical compositions demonstrates his commitment to advancing drug delivery systems. His contributions continue to influence the field and improve patient outcomes.